Paul Lapco, MD
Otolaryngology · Pompano Beach, FLNPI 1174587331
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,758 of the $12,529 with a category attached, or 69.9%. 18 manufacturers reported payments, led by Stryker at 42.8% of the total. Among otolaryngology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $54.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$5K
- Aerin Medical Inc.$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi$1K
- Medtronic$880
- Acclarent, Inc$575
- plus $1K from 12 others
Across 62 payments — averaging $605.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biohaven Pharmaceutical Holding Company Ltd.$38K
What the payments were for
- Travel & lodging$3,61529%
- Food & beverage$8,75870%
- Education$1551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 60 | $5,367 |
| Aerin Medical Inc. | 19 | $2,009 |
| Regeneron Healthcare Solutions, Inc. | 41 | $1,274 |
| Sanofi | 29 | $1,021 |
| Medtronic | 15 | $880 |
| Acclarent, Inc | 13 | $575 |
| Optinose US, Inc. | 25 | $544 |
| Intersect ENT, Inc. | 9 | $457 |
| GSK | 5 | $105 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Hikma Pharmaceuticals USA | 4 | $65 |
| Neurent Medical Limited | 1 | $25 |
| Amgen | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Olympus America Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Kaleo, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTELLUS - XPRESS ENT DILATION SYSTEM$1,592
- XPRESS ENT DILATION SYSTEM$1,414
- VivAer$679
- RhinAer$679
- VIVAER STYLUS$676
- FIAGON NAVIGATION UNIT$541
- DUPIXENT$472
- PROPEL$425
- STEALTHSTATION S8 PLATFORM$277
- SINUVA$149
- SCOPIS ENT$105
- ENTELLUS - XEROGEL NASAL/EPISTAXIS PACK$102
How this compares
$12,529 in reported general payments places this provider in the 90th percentile of 586 otolaryngology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XhanceFluticasone Propionate | 20 | $15,856 |
| Ipratropium Bromide | 201 | $4,285 |
| Montelukast Sodium | 295 | $3,075 |
| Azelastine Hcl | 107 | $2,133 |
| Fluticasone Propionate | 162 | $1,700 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 16 | $1,647 |
| Betamethasone Dipropionate | 35 | $1,213 |
| Mupirocin | 166 | $1,004 |
| Fluocinolone Acetonide Oil | 21 | $724 |
| Omeprazole | 67 | $704 |
| Pilocarpine Hcl | 17 | $674 |
| Methylprednisolone | 111 | $667 |
| Nystatin | 24 | $394 |
| Azithromycin | 103 | $385 |
| Ofloxacin | 14 | $326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $544 | $15,85620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 586 otolaryngology providers in Florida.
Other otolaryngology in Pompano Beach
- Cecelia DamaskOrlando$707K
- Ralph TufanoSarasota$469K
- Franklin RimellFort Myers$314K
- David BrodnerBoynton Beach$209K
- Maria SuurnaMiami$189K
- Jane DillonOrmond Beach$180K
- Jeb JusticeGainesville$142K
- Indranil DebnathWinter Park$109K
- Agustin ArrietaMiami$95K
- John WestineGainesville$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.